Literature DB >> 31456188

Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers.

Bernhard Biersack1, Rainer Schobert2.   

Abstract

Breast cancer represents the major cause of death in female cancer patients. New efficient treatments are desperately needed, particularly especially for patients suffering from advanced stages and metastases, or those who are no longer responding to the clinically established drugs such as cisplatin or carboplatin. New promising therapy regimens and platinum complexes have emerged over the last few years that displayed efficacy in advanced platinum- and/or drug-resistant breast tumors and metastases. This chapter provides an overview of the latest developments in the field of platinum-based drugs against advanced and resistant breast cancers since 2013.

Entities:  

Keywords:  Anticancer agents; Breast cancer; Metastasis; Multidrug resistance (MDR); Platinum complexes; Triple-negative breast cancer (TNBC)

Mesh:

Substances:

Year:  2019        PMID: 31456188     DOI: 10.1007/978-3-030-20301-6_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3-phospho-BAD pathway.

Authors:  Xiaolin Guan; Xin Meng; Keyu Zhu; Jinyan Kai; Yixuan Liu; Qian Ma; Ying Tong; Hui Zheng; Suhong Xie; Xiaolu Ma; Yanchun Wang; Renquan Lu; Lin Guo
Journal:  Cell Death Discov       Date:  2022-02-26

Review 2.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.